|Day Low/High||100.42 / 103.74|
|52 Wk Low/High||98.38 / 135.89|
Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.
Questions about the staying power of the present market turn are crucial for portfolio positioning.
As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.
Here's why down-and-out Medtronic could see a good year ahead.
Assigning the central bank responsibilities extending beyond the adjustment of monetary policy creates an unknown that I do not think we can assume outcomes for.
The fiscal football remains a greater threat this week than anything Fed Chair Jerome Powell says on Zoom this Friday.
These companies were counted out way too early in the post-pandemic environment and the sellers are experiencing some real regret.
The banks are parking large amounts of dough at the Fed every night. Last Friday's number was the highest single day total since 2017.
The upcoming earnings report will also be an indicator.
Here's our longer-term price objective.
Cryptos and cash are both headed for a real fight. For their own existence.
If all goes well, JNJ could be able to immunize a billion individuals this year just by themselves.
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
The technical indicators are mixed for the big medical device maker and suggest bulls are not strongly behind the latest advance in the shares.
With Medtronic, momentum and trend are turning higher along with the breakout.
Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.
MDT is set to report earnings on Tuesday.
I would look for some sideways to lower price action in the weeks ahead.
These names combine healthcare research with state-of-the art technology.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'